SLC5A2 and cardiac hypertrophy: Interestingly, treatment with the SGLT2 inhibitor ipragliflozin reduced both miR-144-3p expression and cardiac hypertrophy in Dahl-sensitive obese rats, suggesting potential tissue- or disease-specific effects of miR-144-3p, such as having protective effects during early remodeling but contributing to maladaptive responses in later stages or under different metabolic conditions [46].